Pacific Biosciences of California, Inc.

PACB·NasdaqGS·Healthcare
Compare
2.5500+0.1100 (+4.51%)today
At close: Nov 4, 4:00 PM EST · May be delayed up to 15 min · USD
Pre-market2.5000−0.0500 (−1.96%)

Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.

Key statistics

Previous close2.4400
Open2.5300
Day range2.48002.7000
52-week range1.07003.4400
Off day high−5.56%
Off 52-week high−25.87%
Volume20.92M
Avg. volume (3M)12.10M
Market cap792.62M
EPS (TTM)-0.4300
Forward P/E-6.05
P/E ratio (TTM)—
Dividend yield—
Beta (5Y)2.20
Shares outstanding310.83M
Short interest17.36% of float
Earnings dateNov 4, 2026
Analyst target2.5429
Profit margin−82.49%

Against its peers

Compare in full ›
PACB TXG LAB 2170.HK QSI CTKB
Market cap 792.62M 8.80B 243.14M 372.96M 282.36M 764.30M
P/E (TTM) — — — — — —
Forward P/E -6.1 880.7 -61.6 -5.3 -3.7 84.0
Price/book 141.7 10.7 0.4 0.4 1.6 2.2
Dividend yield — — — — — —
1-year change +27.08% +383.99% −46.49% −43.28% −27.78% +48.63%
Today +4.51% +3.42% +0.85% +1.11% −0.77% −1.34%

The closest companies by business and industry (Medical Devices). Prices may be delayed up to 15 min.

Latest news

All PACB news ›
The Globe and Mail·Negative

PacBio (NASDAQ:PACB) Misses Q1 CY2026 Sales Expectations

Genomics company Pacific Biosciences of California (NASDAQ:PACB) fell short of the market’s revenue expectations in Q1 CY2026, with sales flat year on year at $37.18 million. Its non-GAAP loss of $0.12 per share was 8.7% above analysts’…

markets.businessinsider.com·Positive

PacBio to Participate in Upcoming Investor Conferences

MENLO PARK, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will be ... PacBio to Participate in Upcoming Investor…

markets.businessinsider.com·Positive

PacBio price target raised to $2.50 from $1.50 at Stephens

Stephens analyst Mason Carrico raised the firm’s price target on PacBio (PACB) to $2.50 from $1.50 and keeps an Overweight rating on the shares ... PacBio price target raised to $2.50 from $1.50 at Stephens Stephens analyst Mason Carrico…

From the 4Search news index, newest first.

In the news

28mentions in 30 days
8with it in the headline
Positivesentiment

Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 28 articles, not a forecast.

Market data is provided for information only and comes from free public sources. Prices may be delayed up to 15 minutes; data may be incomplete or inaccurate. Nothing on this page is investment advice or a recommendation to buy or sell any security. News and coverage analytics are drawn from the 4SEARCH.business index. Terms of use. How to use Finance